Company: Henan Lingrui Pharmaceutical Company Limited
Bloomberg ticker: 600285 SH
Market cap: US$1,391m
Background: Henan Lingrui Pharmaceutical Company Limited engages in R&D, production, and distribution of medicines. The product range includes emplastrum, tablets, capsules, ointments, applied in the treatment of diabetes mellitus, osteoarthritis, gastropathy, cardiovascular and cerebrovascular diseases, respiratory disease, gynecopathy and dermatopathy.
World Class Benchmarking of Henan Lingrui Pharmaceutical
- Profitable Growth rank of 2 was same compared to the prior period’s 2nd rank
- This is World Class performance compared to 390 medium Health Care companies worldwide
- Profitability rank of 2 was better than its Growth rank of 4
- Profitability rank of 2 was the same compared to the prior period’s 2nd rank
- This is World Class performance compared to peers
- Growth rank of 4 was down compared to the prior period’s 3rd rank
- This is above average performance compared to peers
DISCLAIMER: This content is for information purposes only. It is not intended to be investment advice. Readers should not consider statements made by the author(s) as formal recommendations and should consult their financial advisor before making any investment decisions. While the information provided is believed to be accurate, it may include errors or inaccuracies. The author(s) cannot be held liable for any actions taken as a result of reading this article.